• Explore /
  • Poster
  • / Phase II trial assessing safety and preliminary efficacy of high-dose intravenous ascorbic acid in patients with <em>TET2-</em>mutant clonal cytopenias of undetermined significance.

Phase II trial assessing safety and preliminary efficacy of high-dose intravenous ascorbic acid in patients with TET2-mutant clonal cytopenias of undetermined significance.

Abstract Poster

Authors

null

Zhuoer Xie

Mayo Clinic, Rochester, MN

Zhuoer Xie , Terra L. Lasho , Jenna Fernandez , Christy Finke , Michelle Amundson , Betsy LaPlant , Abhishek Avinash Mangaonkar , Thomas E. Witzig , Mrinal Mahesh Patnaik

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Myelodysplastic Syndromes (MDS)

Clinical Trial Registration Number

NCT03418038

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS7076)

DOI

10.1200/JCO.2022.40.16_suppl.TPS7076

Abstract #

TPS7076

Poster Bd #

300b

Abstract Disclosures

Similar Posters

First Author: John Ebben

Poster

2023 ASCO Genitourinary Cancers Symposium

A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.

A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.

First Author: Jianbo Wang

First Author: Tony R. Reid

First Author: Seiichi Hayato